Please use this identifier to cite or link to this item:
https://doi.org/10.1186/s12957-022-02817-6
DC Field | Value | |
---|---|---|
dc.title | Locally invasive recurrence or metastasis of pheochromocytoma into the liver?—clinicopathological challenges | |
dc.contributor.author | Tang, Sarah S | |
dc.contributor.author | Lee, James WK | |
dc.contributor.author | Wijerethne, Sujith | |
dc.contributor.author | Iyer, Shridhar Ganpathi | |
dc.contributor.author | Hue, Susan | |
dc.contributor.author | En, Nga Min | |
dc.contributor.author | Parameswaran, Rajeev | |
dc.date.accessioned | 2022-11-15T00:39:33Z | |
dc.date.available | 2022-11-15T00:39:33Z | |
dc.date.issued | 2022-11-11 | |
dc.identifier.citation | Tang, Sarah S, Lee, James WK, Wijerethne, Sujith, Iyer, Shridhar Ganpathi, Hue, Susan, En, Nga Min, Parameswaran, Rajeev (2022-11-11). Locally invasive recurrence or metastasis of pheochromocytoma into the liver?—clinicopathological challenges. World Journal of Surgical Oncology 20 (1). ScholarBank@NUS Repository. https://doi.org/10.1186/s12957-022-02817-6 | |
dc.identifier.issn | 1477-7819 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/234519 | |
dc.description.abstract | <jats:title>Abstract</jats:title><jats:p>Pheochromocytomas (PCC) are rare and functional neuroendocrine tumors developing from adrenal chromaffin cells. Predicting malignant behavior especially in the absence of metastasis can be quite challenging even in the era of improved understanding of the molecular mechanisms involved in PCCs. Currently, two histopathological grading systems Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) score are used in clinical practice, but these are subject to significant interobserver variability. Some of the most useful clinical factors associated with malignancy are large size ([4–5 cm), and genetic features such as presence of SDHB germline mutations. Local invasion is uncommon in PCC and metastasis seen in 10 to 17% but higher in germline mutations and when this occurs management can be challenging. Here, we report on a case with challenges faced by the pathologist and clinicians alike in diagnosis and management of PCC recurrence.</jats:p> | |
dc.publisher | Springer Science and Business Media LLC | |
dc.source | Elements | |
dc.type | Article | |
dc.date.updated | 2022-11-15T00:11:49Z | |
dc.contributor.department | PATHOLOGY | |
dc.contributor.department | SURGERY | |
dc.description.doi | 10.1186/s12957-022-02817-6 | |
dc.description.sourcetitle | World Journal of Surgical Oncology | |
dc.description.volume | 20 | |
dc.description.issue | 1 | |
dc.published.state | Unpublished | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Tang_et_al-2022-World_Journal_of_Surgical_Oncology.pdf | Published version | 2.23 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.